Ventricular Tachycardia

Ventricular tachycardia (VT) is a cardiac arrhythmia originating from the ventricular myocardium or the specialized conduction system distal to the His bundle, characterized by a rapid, regular, or occasionally irregular ventricular rate. In veterinary medicine, VT is defined as a run of three or more consecutive ventricular premature complexes (VPCs) at a heart rate exceeding the upper limit of normal for the species and age. In dogs, this typically corresponds to a ventricular rate greater than 160-180 beats per minute (bpm), while in cats, rates exceeding 240 bpm are often observed. VT can be classified based on duration (sustained vs. nonsustained), morphology (monomorphic vs. polymorphic), and underlying etiology (primary electrical disease vs. secondary to structural heart disease or systemic disorders). Sustained VT lasts more than 30 seconds or requires intervention due to hemodynamic compromise, whereas nonsustained VT terminates spontaneously within 30 seconds. Monomorphic VT has a single QRS morphology, indicating a single ectopic focus or reentrant circuit, while polymorphic VT exhibits varying QRS morphologies, suggesting multiple foci or unstable reentry, and includes torsades de pointes when associated with QT prolongation. VT is a life-threatening arrhythmia that can degenerate into ventricular fibrillation (VF) and cause sudden cardiac death. It is a common clinical emergency in dogs, particularly in breeds predisposed to arrhythmogenic right ventricular cardiomyopathy (ARVC), and is less common in cats, where it often occurs secondary to hypertrophic cardiomyopathy (HCM) or systemic diseases such as hyperthyroidism.

The etiologies of ventricular tachycardia are diverse and can be categorized into primary cardiac disorders, systemic diseases, toxicities, and iatrogenic causes. Primary cardiac causes include structural heart diseases such as dilated cardiomyopathy (DCM), particularly in large-breed dogs like Doberman Pinschers, Boxers, and Great Danes, where myocardial fibrosis and fatty infiltration disrupt electrical conduction. Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a heritable condition in Boxers and Bulldogs characterized by fibrofatty replacement of the right ventricular myocardium, predisposing to VT. Myocarditis, whether infectious (e.g., parvovirus, canine distemper virus, Borrelia burgdorferi, Trypanosoma cruzi) or immune-mediated, can cause myocardial inflammation and electrical instability. Myocardial infarction, though rare in dogs and cats due to collateral coronary circulation, can lead to ischemic VT. Valvular heart disease, especially chronic mitral valve disease (CMMVD) in small-breed dogs, can cause atrial enlargement and secondary ventricular arrhythmias. Congenital heart diseases, such as subaortic stenosis, can cause myocardial ischemia and VT. Systemic causes include electrolyte imbalances, particularly hypokalemia, hypomagnesemia, hypercalcemia, and acid-base disturbances, which alter myocardial cell membrane potentials. Hypoxemia and anemia can cause myocardial ischemia. Endocrine disorders such as hypothyroidism, hyperthyroidism (especially in cats), and pheochromocytoma (catecholamine excess) can trigger VT. Sepsis and systemic inflammatory response syndrome (SIRS) can cause myocardial depression and arrhythmias. Toxicities are common causes: digitalis glycosides, calcium channel blockers, beta-agonists (e.g., albuterol), theobromine (chocolate), caffeine, and certain plants (e.g., foxglove, oleander) can induce VT. Iatrogenic causes include cardiac catheterization, pacemaker lead placement, and administration of proarrhythmic drugs such as dobutamine, dopamine, or volatile anesthetics (e.g., halothane). In cats, VT is often associated with hypertrophic cardiomyopathy (HCM), hyperthyroidism, or systemic hypertension. Additionally, idiopathic VT can occur in young, otherwise healthy dogs, particularly in breeds like Labrador Retrievers and German Shepherds, where the arrhythmia may be exercise-induced.

Ventricular tachycardia is predominantly a disease of dogs, with a higher incidence in certain breeds due to genetic predispositions. Boxers are notably predisposed to ARVC, with an estimated prevalence of 30-50% in some lines, and VT is a common manifestation. Doberman Pinschers have a high prevalence of DCM, with up to 60% developing ventricular arrhythmias, including VT, often preceding systolic dysfunction. Other breeds at risk include Great Danes, Irish Wolfhounds, and English Bulldogs. In cats, VT is less common but can occur in association with HCM, which is the most prevalent cardiac disease in cats, affecting approximately 15% of the general feline population. VT in cats is also seen in hyperthyroidism, systemic hypertension, and myocarditis. Age distribution varies: ARVC in Boxers typically manifests in middle-aged to older dogs (5-7 years), while DCM in Dobermans often presents between 4-10 years. Idiopathic VT in young dogs (1-3 years) is also recognized. Sex predilections are not consistently reported, but some studies suggest a male predominance in Dobermans with DCM. Geographic variations are minimal, but vector-borne diseases like Chagas disease (Trypanosoma cruzi) in endemic regions (e.g., South America, southern United States) can cause myocarditis and VT. Overall, VT is a significant cause of morbidity and mortality, with sudden cardiac death being a common outcome, particularly in Boxers and Dobermans.

The pathophysiology of ventricular tachycardia involves abnormal impulse formation (enhanced automaticity, triggered activity) or reentry. Enhanced automaticity occurs when ventricular myocytes or Purkinje fibers depolarize spontaneously at an accelerated rate, often due to increased sympathetic tone, hypokalemia, or ischemia. Triggered activity results from early afterdepolarizations (EADs) or delayed afterdepolarizations (DADs), which are oscillations in membrane potential that can reach threshold and initiate an action potential. EADs are associated with prolonged action potential duration (e.g., due to QT prolongation) and are exacerbated by bradycardia, hypokalemia, and certain drugs (e.g., class III antiarrhythmics). DADs are caused by intracellular calcium overload, often due to digitalis toxicity, catecholamines, or myocardial ischemia, and are enhanced by rapid heart rates. Reentry is the most common mechanism for sustained VT and requires a circuit with unidirectional block and slow conduction, often around areas of myocardial fibrosis, scar, or anatomical obstacles. In DCM and ARVC, fibrofatty infiltration creates zones of slow conduction and block, facilitating reentrant circuits. In acute ischemia, heterogeneous electrical properties between normal and ischemic tissue promote reentry. The hemodynamic consequences of VT depend on the ventricular rate, duration, and underlying cardiac function. Rapid VT reduces diastolic filling time, decreases stroke volume, and can lead to hypotension, syncope, pulmonary edema, and cardiogenic shock. Sustained VT can degenerate into ventricular fibrillation, leading to cardiac arrest. Additionally, VT can cause myocardial ischemia due to increased oxygen demand and reduced coronary perfusion, further perpetuating arrhythmias. Neurohumoral activation, including sympathetic stimulation and renin-angiotensin-aldosterone system activation, can exacerbate the arrhythmia and contribute to adverse remodeling.

Predisposing factors for ventricular tachycardia include breed-specific genetic mutations, such as the striatin gene mutation in Boxers with ARVC and the PDK4 gene mutation in Dobermans with DCM. Age is a risk factor, with middle-aged to older dogs more commonly affected by structural heart disease, while young dogs may have idiopathic VT. Sex may play a role, with some studies suggesting a higher risk in males. Concurrent systemic diseases, such as hypothyroidism, hyperthyroidism, diabetes mellitus, and electrolyte imbalances (hypokalemia, hypomagnesemia, hypercalcemia), increase susceptibility. Hypoxemia from respiratory disease or anemia can predispose to VT. Acid-base disturbances, particularly acidosis, can alter myocardial excitability. Medications that prolong QT interval (e.g., certain antiarrhythmics, antibiotics like fluoroquinolones, antifungals) or increase sympathetic tone (e.g., bronchodilators, decongestants) can trigger VT. Stress, excitement, and intense exercise can precipitate VT in susceptible animals due to increased catecholamine release. Cardiac conditions such as myocarditis, myocardial infarction, and cardiac tumors (e.g., hemangiosarcoma) are direct predisposing factors. In cats, hyperthyroidism and systemic hypertension are significant risk factors. Additionally, iatrogenic factors, including cardiac surgery, pacemaker implantation, and anesthesia with arrhythmogenic agents, can predispose to VT.

Clinical signs of ventricular tachycardia vary from asymptomatic to sudden death. In dogs, nonsustained VT may be an incidental finding on auscultation or electrocardiography (ECG) during a routine examination, with no overt clinical signs. When VT is sustained or rapid, signs include weakness, lethargy, exercise intolerance, syncope or collapse, and signs of congestive heart failure such as dyspnea, cough, and tachypnea. Physical examination may reveal an irregularly irregular or rapid heart rate, pulse deficits, weak femoral pulses, pale mucous membranes, and prolonged capillary refill time. In severe cases, signs of cardiogenic shock, including hypothermia, cold extremities, and altered mentation, may be present. In cats, VT may present with similar signs, but syncope and sudden death are more common. Cats with HCM may show signs of thromboembolism, such as hindlimb paresis, if concurrent atrial fibrillation or other arrhythmias are present. Some animals may exhibit gastrointestinal signs like vomiting or diarrhea due to reduced cardiac output and visceral ischemia. The clinical signs can be categorized by stage: peracute (sudden death), acute (syncope, collapse, severe weakness), subacute (intermittent weakness, exercise intolerance), and chronic (progressive signs of heart failure). Subtle early indicators include mild exercise intolerance, increased sleeping respiratory rate, and occasional coughing, which may be overlooked by owners.

Differential diagnoses for ventricular tachycardia include other tachyarrhythmias and conditions that cause syncope or collapse. Key differentials include: 1) Supraventricular tachycardia (SVT) with aberrant conduction, which can mimic VT on ECG; differentiation is crucial as treatment differs. SVT typically has a narrow QRS complex unless aberrancy is present, and vagal maneuvers may slow or terminate it. 2) Atrial fibrillation (AF) with rapid ventricular response, especially in large-breed dogs with DCM; AF is characterized by an irregularly irregular rhythm and absent P waves. 3) Sinus tachycardia, which is a regular rhythm with normal P waves and a gradual onset/offset; it is a physiological response to stress, pain, fever, or hypovolemia. 4) Ventricular premature complexes (VPCs) that occur in a bigeminal or trigeminal pattern, which may be mistaken for VT if runs are short. 5) Myocarditis, which can cause VT but is a specific etiology. 6) Dilated cardiomyopathy (DCM) and arrhythmogenic right ventricular cardiomyopathy (ARVC) are structural causes of VT. 7) Electrolyte imbalances, such as hyperkalemia, can cause bizarre QRS complexes that mimic VT. 8) Toxicity, such as digitalis or chocolate ingestion, can cause VT. 9) Hypothyroidism or hyperthyroidism can cause arrhythmias. 10) Syncope due to non-cardiac causes, such as vasovagal syncope, seizures, or hypoglycemia, must be differentiated from arrhythmic syncope. Definitive diagnosis relies on ECG, Holter monitoring, echocardiography, and laboratory tests to rule out systemic causes.

The diagnostic approach to ventricular tachycardia begins with a thorough history and physical examination, including cardiac auscultation and palpation of femoral pulses. If VT is suspected or detected on ECG, the following stepwise algorithm is recommended: 1) Immediate assessment of hemodynamic stability: if the animal is unstable (hypotension, syncope, pulmonary edema), emergency treatment with antiarrhythmics and electrical cardioversion may be indicated before further diagnostics. 2) Obtain a 6-lead ECG to confirm VT, assess heart rate, QRS morphology, and identify any underlying rhythm (e.g., sinus rhythm with VPCs). 3) Perform a complete blood count, serum biochemistry panel, and electrolyte measurements (potassium, magnesium, calcium) to identify metabolic or electrolyte abnormalities. 4) Measure cardiac troponin I (cTnI) to assess myocardial injury. 5) Perform thoracic radiographs to evaluate heart size, pulmonary vasculature, and signs of congestive heart failure. 6) Echocardiography is essential to evaluate cardiac structure and function, including left ventricular dimensions, wall thickness, fractional shortening, and presence of valvular disease or pericardial effusion. 7) If structural heart disease is not evident, consider 24-hour Holter monitoring to document the frequency and complexity of ventricular arrhythmias, especially in breeds predisposed to ARVC or DCM. 8) In cases of suspected myocarditis, consider infectious disease testing (e.g., PCR for vector-borne diseases, titers for Borrelia, Ehrlichia, Anaplasma). 9) If a pheochromocytoma is suspected, measure plasma or urine metanephrines. 10) In refractory or atypical cases, advanced imaging such as cardiac MRI may be indicated to detect myocardial fibrosis or infiltration. 11) Electrophysiological studies are rarely performed in veterinary medicine but may be used in specialized centers to map arrhythmogenic foci. The diagnostic algorithm should be tailored to the individual patient, with priority given to life-threatening conditions.

Laboratory findings in ventricular tachycardia are often nonspecific but can reveal underlying causes. Complete blood count (CBC) may show leukocytosis or left shift if infection or inflammation is present, or anemia if hypoxemia is a trigger. Serum biochemistry may reveal electrolyte imbalances: hypokalemia (potassium < 3.5 mEq/L) is a common trigger and can be due to diuretic use, vomiting, or hyperaldosteronism; hypomagnesemia (magnesium < 1.5 mg/dL) can predispose to arrhythmias; hypercalcemia (calcium > 12 mg/dL) can occur with hyperparathyroidism or malignancy. Acid-base disturbances, such as metabolic acidosis (pH < 7.35) or alkalosis, can be detected on blood gas analysis. Cardiac troponin I (cTnI) is a sensitive and specific biomarker for myocardial injury; elevated levels (> 0.03 ng/mL in dogs, > 0.1 ng/mL in cats) suggest myocarditis, ischemia, or trauma. NT-proBNP (N-terminal pro-B-type natriuretic peptide) may be elevated in heart failure and can help differentiate cardiac from non-cardiac causes of dyspnea. In dogs with DCM, NT-proBNP levels are often > 900 pmol/L. Thyroid function tests (total T4, free T4, TSH) are indicated in cats to rule out hyperthyroidism. In suspected pheochromocytoma, plasma or urine metanephrine levels are elevated. Serology or PCR for infectious agents (e.g., Ehrlichia, Anaplasma, Borrelia, Bartonella, Trypanosoma cruzi) may be positive in myocarditis. Urinalysis may reveal proteinuria or casts if systemic hypertension or renal disease is present. Blood gas analysis can assess oxygenation and ventilation, especially if pulmonary edema is present. Additional biomarkers such as C-reactive protein (CRP) may be elevated in inflammatory conditions. It is important to interpret laboratory findings in conjunction with clinical signs and imaging.

Imaging plays a crucial role in the evaluation of ventricular tachycardia. Thoracic radiographs are essential to assess heart size (vertebral heart score, VHS; normal < 10.5 in dogs, < 8 in cats), pulmonary vasculature, and signs of congestive heart failure such as pulmonary edema (interstitial or alveolar pattern) or pleural effusion. Radiographs may also reveal underlying conditions like megaesophagus (common in myasthenia gravis, which can cause aspiration pneumonia and arrhythmias) or pulmonary masses. Echocardiography is the gold standard for evaluating cardiac structure and function. In dogs with DCM, echocardiography reveals left ventricular dilation (end-diastolic diameter > 40 mm in Dobermans), reduced fractional shortening (< 25%), and increased E-point to septal separation (EPSS). In Boxers with ARVC, echocardiography may show right ventricular dilation, reduced right ventricular systolic function, and wall motion abnormalities, though the disease can be occult. In cats with HCM, echocardiography shows concentric left ventricular hypertrophy (wall thickness > 6 mm) and often left atrial enlargement. Echocardiography can also detect valvular disease, pericardial effusion, and cardiac masses (e.g., hemangiosarcoma of the right atrium). Doppler echocardiography can assess diastolic function and estimate pulmonary artery pressure. Advanced imaging such as cardiac MRI can detect myocardial fibrosis (late gadolinium enhancement) and fatty infiltration, which are characteristic of ARVC. Computed tomography (CT) may be used to evaluate for pulmonary thromboembolism or cardiac masses. In emergency settings, point-of-care ultrasound (POCUS) can quickly assess cardiac function and pericardial effusion. Imaging findings guide treatment decisions and prognosis.

Cytology and histopathology are primarily used to diagnose underlying myocardial diseases. Fine needle aspiration (FNA) of cardiac masses (e.g., right atrial hemangiosarcoma) can yield cytological evidence of malignant mesenchymal cells, which are spindle-shaped with high nuclear-to-cytoplasmic ratio and anisocytosis. In myocarditis, FNA is rarely performed due to risk, but if done, it may show inflammatory cells (lymphocytes, plasma cells, neutrophils) and myocyte degeneration. Histopathology of myocardial biopsies (obtained via endomyocardial biopsy or at necropsy) is the gold standard for diagnosing ARVC, DCM, and myocarditis. In ARVC, histopathology reveals fibrofatty replacement of the right ventricular myocardium, with myocyte atrophy and fibrosis. In DCM, histopathology shows myocyte hypertrophy, attenuation, and interstitial fibrosis. In myocarditis, there is an inflammatory infiltrate (lymphocytic, neutrophilic, or eosinophilic) with myocyte necrosis. Special stains such as Masson's trichrome can highlight fibrosis, and immunohistochemistry for immune cells (CD3, CD20) can characterize the inflammatory infiltrate. In cases of Chagas disease, amastigotes of Trypanosoma cruzi may be seen within myocytes. Histopathology is also useful to diagnose cardiac tumors, such as hemangiosarcoma, which shows vascular channels lined by pleomorphic endothelial cells. In cats with HCM, histopathology shows myocyte disarray, hypertrophy, and interstitial fibrosis. Cytology of pericardial fluid may be performed if pericardial effusion is present; hemorrhagic effusion with neoplastic cells suggests cardiac neoplasia, while exudative effusion may indicate infectious pericarditis. Histopathology is essential for definitive diagnosis and can guide prognosis and treatment.

Treatment of ventricular tachycardia depends on the hemodynamic stability of the patient and the underlying cause. In unstable animals (hypotension, syncope, pulmonary edema), immediate emergency therapy is required. The first-line antiarrhythmic for acute management is lidocaine, a class IB agent, administered as an intravenous bolus of 2 mg/kg (dogs) or 0.25-0.5 mg/kg (cats) over 1-2 minutes, followed by a continuous rate infusion (CRI) at 25-80 mcg/kg/min (dogs) or 10-40 mcg/kg/min (cats). If lidocaine is ineffective, procainamide (class IA) can be given at 10-15 mg/kg IV over 10-20 minutes, followed by CRI at 20-50 mcg/kg/min. Amiodarone (class III) is a potent antiarrhythmic for refractory VT, administered as a slow IV bolus of 5 mg/kg over 20-30 minutes, followed by CRI at 10-15 mg/kg/day. In cases of cardiac arrest or pulseless VT, electrical cardioversion (synchronized shock) is indicated, with an initial energy of 0.5-1 J/kg for dogs and 0.25-0.5 J/kg for cats. For stable animals, oral antiarrhythmics are used. Sotalol (class III) is commonly used at 1-2 mg/kg PO q12h in dogs and 1-2 mg/kg PO q12h in cats. Mexiletine (class IB) can be used at 4-8 mg/kg PO q8h in dogs, often in combination with sotalol or beta-blockers. Beta-blockers such as atenolol (0.25-1 mg/kg PO q12h in dogs; 6.25-12.5 mg/cat PO q12h) or propranolol (0.2-1 mg/kg PO q8h) may be used, especially if VT is exacerbated by sympathetic tone. In cases of electrolyte imbalances, correction is essential: potassium supplementation (0.5-1 mEq/kg/day PO or IV) for hypokalemia, magnesium sulfate (0.5-1 mEq/kg IV over 20 minutes) for hypomagnesemia. Underlying diseases must be treated: for DCM, pimobendan (0.3 mg/kg PO q12h) and ACE inhibitors (enalapril 0.5 mg/kg PO q12h) are indicated; for HCM in cats, atenolol or diltiazem (1-2 mg/kg PO q8h) may be used. In cases of myocarditis, immunosuppressive doses of prednisone (1-2 mg/kg/day) may be considered, but only after ruling out infectious causes. For ARVC in Boxers, sotalol is the drug of choice, often combined with mexiletine. In refractory cases, catheter ablation of the arrhythmogenic focus may be an option in specialized centers. Supportive care includes oxygen therapy for hypoxemia, diuretics (furosemide 1-2 mg/kg IV or PO) for congestive heart failure, and antiemetics if vomiting occurs. Continuous ECG monitoring is essential during acute treatment.

The prognosis for ventricular tachycardia varies widely depending on the underlying cause, the presence of structural heart disease, and the response to therapy. In dogs with idiopathic VT and no structural heart disease, the prognosis is generally good, with many animals living normal lives with appropriate antiarrhythmic therapy. However, in breeds with ARVC (Boxers), the prognosis is guarded, as the disease is progressive and can lead to sudden cardiac death; median survival times range from 6 months to 2 years after diagnosis. In Dobermans with DCM and VT, the prognosis is poor, with a median survival of 3-6 months after the onset of congestive heart failure, and sudden death is common. In cats with HCM and VT, the prognosis is also guarded, with a median survival of 1-2 years after diagnosis, depending on the severity of hypertrophy and presence of heart failure. Negative prognostic indicators include: sustained VT, polymorphic VT, high frequency of VPCs (> 10,000/24 hours on Holter), syncope, congestive heart failure, elevated cardiac troponin I, and poor response to antiarrhythmic therapy. Animals that survive the initial episode and respond to treatment may have a better prognosis. Regular monitoring and adjustment of therapy are essential to improve outcomes. In cases of VT secondary to reversible causes (e.g., electrolyte imbalance, toxin exposure), the prognosis is excellent if the underlying cause is corrected promptly.

Follow-up care for ventricular tachycardia is critical to monitor response to therapy and adjust medications. Initially, animals should be re-evaluated within 1-2 weeks after starting antiarrhythmic therapy. A 6-lead ECG should be performed at each recheck to assess heart rate and rhythm, and a 24-hour Holter monitor is recommended every 3-6 months to quantify VPC frequency and detect runs of VT. Serum electrolyte levels (potassium, magnesium) should be checked regularly, especially if diuretics are used. Cardiac troponin I can be measured to monitor myocardial injury. Echocardiography should be repeated every 6-12 months to assess progression of structural heart disease. In dogs with DCM, thoracic radiographs should be repeated if signs of congestive heart failure develop. Owners should be educated to monitor resting respiratory rate at home; an increase above 30 breaths per minute may indicate pulmonary edema. Antiarrhythmic drug dosages may need adjustment based on Holter results and clinical signs; for example, if VPC frequency increases, the dose of sotalol or mexiletine may be increased, or a different drug added. In cats, thyroid function should be monitored if hyperthyroidism is treated. Long-term management includes dietary modifications (e.g., low-sodium diet in heart failure), weight management, and restriction of strenuous exercise. In breeds with genetic predispositions, screening of related animals is recommended. Regular follow-up with a veterinary cardiologist is advised for complex cases.

Pearls: 1) Always assess pulse quality and mucous membrane color in any tachyarrhythmia; a weak pulse with a rapid heart rate suggests VT or SVT with hemodynamic compromise. 2) Lidocaine is the first-line drug for VT in dogs; it is effective and has a short half-life, allowing rapid titration. 3) In cats, lidocaine should be used with caution at lower doses due to increased sensitivity; amiodarone or sotalol may be preferred. 4) Always check electrolytes, especially potassium and magnesium, before starting antiarrhythmics; hypokalemia can render antiarrhythmics ineffective. 5) In Boxers with suspected ARVC, a Holter monitor is essential for diagnosis, as echocardiography may be normal in early stages. 6) In Dobermans, the presence of > 100 VPCs in 24 hours is a risk factor for sudden death; consider antiarrhythmic therapy even if asymptomatic. 7) For unstable VT, electrical cardioversion is the fastest way to restore sinus rhythm; do not delay if the animal is collapsing. 8) Amiodarone is a potent drug but has significant side effects (hepatotoxicity, thyroid dysfunction); monitor liver enzymes and thyroid levels periodically. 9) In cats with HCM and VT, beta-blockers like atenolol are preferred over sotalol due to less proarrhythmic risk. 10) Always consider toxin exposure (e.g., chocolate, lilies) in acute onset VT, especially in young animals. Pitfalls: 1) Mistaking VT for SVT with aberrancy can lead to inappropriate treatment with calcium channel blockers, which can worsen VT. 2) Using lidocaine in cats without dose adjustment can cause seizures and cardiac arrest. 3) Failing to correct hypokalemia before giving antiarrhythmics can lead to refractory VT. 4) Overlooking underlying structural heart disease can lead to inappropriate therapy and progression of heart failure. 5) Discontinuing antiarrhythmics abruptly can cause rebound VT; taper doses gradually. 6) In Boxers, using sotalol alone may not control VT; combination with mexiletine is often needed. 7) In Dobermans, using digoxin for heart failure can exacerbate VT; avoid if possible. 8) Not monitoring Holter after starting therapy can lead to underdosing or overdosing. 9) In cats, using amiodarone can cause severe pulmonary fibrosis; reserve for refractory cases. 10) Assuming that a single normal ECG rules out VT; Holter monitoring is necessary for intermittent arrhythmias.

Based on Plumb's Veterinary Drug Handbook, the following drug protocols are recommended for ventricular tachycardia. Emergency treatment: Lidocaine HCl: Dogs: IV bolus 2 mg/kg (max 8 mg/kg total) over 1-2 minutes; if ineffective, may repeat once after 5 minutes; then CRI at 25-80 mcg/kg/min. Cats: IV bolus 0.25-0.5 mg/kg over 2-3 minutes; CRI at 10-40 mcg/kg/min; use with extreme caution. Procainamide: Dogs: IV slow bolus 10-15 mg/kg over 10-20 minutes; then CRI at 20-50 mcg/kg/min; cats: 2-5 mg/kg IV over 5 minutes, then CRI at 10-20 mcg/kg/min. Amiodarone: Dogs: IV 5 mg/kg over 20-30 minutes, then CRI at 10-15 mg/kg/day; cats: not recommended IV due to hypotension; oral dosing: Dogs: 10-15 mg/kg PO q12h for 7 days, then 5-10 mg/kg PO q24h; Cats: 10 mg/kg PO q24h. Oral maintenance: Sotalol: Dogs: 1-2 mg/kg PO q12h; Cats: 1-2 mg/kg PO q12h (start at low end). Mexiletine: Dogs: 4-8 mg/kg PO q8h; Cats: not routinely used. Atenolol: Dogs: 0.25-1 mg/kg PO q12h; Cats: 6.25-12.5 mg/cat PO q12h. Propranolol: Dogs: 0.2-1 mg/kg PO q8h; Cats: 2.5-5 mg/cat PO q8h. For electrolyte correction: Potassium chloride: IV CRI at 0.5-1 mEq/kg/hour for severe hypokalemia; oral supplementation at 1-2 mEq/kg/day divided. Magnesium sulfate: IV 0.5-1 mEq/kg over 20 minutes, then CRI at 0.1-0.3 mEq/kg/hour. For congestive heart failure: Furosemide: Dogs: 1-2 mg/kg IV or PO q8-12h; Cats: 1-2 mg/kg IV or PO q12h. Pimobendan: Dogs: 0.3 mg/kg PO q12h; Cats: 1.25 mg/cat PO q12h. Enalapril: Dogs: 0.5 mg/kg PO q12h; Cats: 0.25-0.5 mg/kg PO q24h. For myocarditis: Prednisone: Dogs: 1-2 mg/kg/day PO, tapering over 4-6 weeks; Cats: 1-2 mg/kg/day PO. Always adjust dosages for renal or hepatic impairment; for example, amiodarone should be used cautiously in hepatic disease, and sotalol requires dose reduction in renal insufficiency. Monitor for drug interactions: beta-blockers and calcium channel blockers can cause bradycardia and hypotension; amiodarone increases digoxin levels; sotalol should not be used with other QT-prolonging drugs.

Key evidence-based literature on ventricular tachycardia in veterinary medicine includes: 1) The ACVIM consensus statement on the diagnosis and treatment of canine dilated cardiomyopathy (DCM) (2019) recommends Holter monitoring for early detection of ventricular arrhythmias in at-risk breeds and suggests that antiarrhythmic therapy (sotalol or mexiletine) be considered when VPC frequency exceeds 100/24 hours or if runs of VT are present. 2) A landmark study by Meurs et al. (2000) identified the striatin gene mutation in Boxers with ARVC, providing a genetic basis for the disease and enabling screening. 3) A study by Calvert et al. (2000) in Doberman Pinschers showed that the presence of > 100 VPCs in 24 hours was associated with a 3-fold increased risk of sudden death, supporting the use of Holter monitoring. 4) A randomized controlled trial by Oyama et al. (2009) compared sotalol and mexiletine for the treatment of ventricular arrhythmias in Boxers and found that combination therapy was more effective than either drug alone. 5) A study by Côté et al. (2011) evaluated the use of amiodarone in dogs with refractory VT and reported a success rate of 70%, but with significant side effects. 6) In cats, a study by Rush et al. (2002) evaluated the use of atenolol in HCM and found a reduction in heart rate and improvement in clinical signs, but no effect on survival. 7) A retrospective study by Ferasin et al. (2003) on cats with VT found that underlying HCM was the most common cause, and that beta-blockers were the most commonly used antiarrhythmics. 8) The ISCAID guidelines on canine myocarditis (2018) recommend a combination of antiarrhythmic therapy and immunosuppressive doses of prednisone if infectious causes are ruled out. 9) A study by Santilli et al. (2016) described the use of radiofrequency catheter ablation for VT in dogs, showing a success rate of 80% in selected cases. 10) A meta-analysis by Pedro et al. (2017) on the use of lidocaine for VT in dogs found that it was effective in 60-70% of cases, with a low incidence of adverse effects. These studies underscore the importance of breed-specific approaches, Holter monitoring, and combination therapy in managing VT.